Indication
Intractable eczema
Intractable eczema refers to a severe, treatment-resistant clinical state of chronic eczematous dermatosis—most commonly atopic dermatitis—that fails to respond adequately to standard topical therapies, such as high-potency corticosteroids or calcineurin inhibitors, and routine trigger-avoidance measures. Read more about Intractable eczema
12 drugs 12 manufacturers
Drugs that treat it
Common Intractable eczema therapies.
PROTOPIC (tacrolimus)
TACROLIMUS
TACROLIMUS
TACROLIMUS
PROTOPIC (tacrolimus)
PIMECROLIMUS
PIMECROLIMUS
PIMECROLIMUS
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonIntractable eczema refers to a severe, treatment-resistant clinical state of chronic eczematous dermatosis—most commonly atopic dermatitis—that fails to respond adequately to standard topical therapies, such as high-potency corticosteroids or calcineurin inhibitors, and routine trigger-avoidance measures.
Affecting the cutaneous system across pediatric and adult populations, it is pathophysiologically driven by persistent immune dysregulation, epidermal barrier dysfunction, and heightened neuroimmune signaling.
Clinically, it is characterized by relentless, debilitating pruritus, extensive xerosis, recurrent erythema, oozing, and lichenification, frequently complicated by secondary cutaneous infections and significant quality-of-life impairment.
- harlanmd.com
Intractable eczema refers to a severe, treatment-resistant clinical state of chronic eczematous dermatosis—most commonly atopic dermatitis—that fails to respond adequately to standard topical therapies, such as high-potency corticosteroids or calcineurin inhibitors, and routine trigger-avoidance measures
- nih.gov
Intractable eczema refers to a severe, treatment-resistant clinical state of chronic eczematous dermatosis—most commonly atopic dermatitis—that fails to respond adequately to standard topical therapies, such as high-potency corticosteroids or calcineurin inhibitors, and routine trigger-avoidance measures Affecting the cutaneous system across pediatric and adult populations, it is pathophysiologically driven by persistent immune dysregulation, epidermal barrier dysfunction, and heightened neuroim...
- nih.gov
Intractable eczema refers to a severe, treatment-resistant clinical state of chronic eczematous dermatosis—most commonly atopic dermatitis—that fails to respond adequately to standard topical therapies, such as high-potency corticosteroids or calcineurin inhibitors, and routine trigger-avoidance measures
- nih.gov
Affecting the cutaneous system across pediatric and adult populations, it is pathophysiologically driven by persistent immune dysregulation, epidermal barrier dysfunction, and heightened neuroimmune signaling Clinically, it is characterized by relentless, debilitating pruritus, extensive xerosis, recurrent erythema, oozing, and lichenification, frequently complicated by secondary cutaneous infections and significant quality-of-life impairment
- nih.gov
Affecting the cutaneous system across pediatric and adult populations, it is pathophysiologically driven by persistent immune dysregulation, epidermal barrier dysfunction, and heightened neuroimmune signaling
- aad.org
Clinically, it is characterized by relentless, debilitating pruritus, extensive xerosis, recurrent erythema, oozing, and lichenification, frequently complicated by secondary cutaneous infections and significant quality-of-life impairment
Personalize your experience
Follow Intractable eczema and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.